Abstract
Over a decade ago, anti-vascular endothelial growth factor (anti-VEGF) injections emerged as a viable treatment for diabetic macular edema (DME), the leading cause of new blindness among working-age adults in North America (1). By targeting VEGF, the signal protein that stimulates abnormal blood vessel growth in DME, the injections offered a new approach to managing vision loss resulting from DME, largely replacing vitrectomy and laser surgery as frontline therapy (2,3). Time-release implants have been used in some cases, as well, and show promise (4).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
